

MASSIVE DYNAMIC

Contact: Mark Johnson
Massive Dynamic Public Affairs
m.johnson@massivedynamic.com

FOR IMMEDIATE RELEASE

Massive Dynamic Announces Surprise Breakthrough in Autoimmune Treatment

NEW YORK CITY, October 22, 2008 – Scientists at Massive Dynamic’s Advanced Pharmaceutical Research Laboratory have found that an experimental treatment for cancer could also defeat a handful of rare life-threatening autoimmune disorders.

“The discovery came as a complete surprise,” said Jason Smith, chief researcher. “Several patients receiving treatment for cancer at our facilities unexpectedly experienced remission of their unrelated autoimmune disorders.”

The treatment involved a new form of simultaneous radiation and chemotherapy for lymphoma patients. “These patients were incredibly lucky,” said Smith. “Normally patients with unrelated illnesses are not admitted to clinical trials. Ironically, their doctors’ failure to diagnose them probably saved their lives.”

Researchers are still unsure of the treatment’s mechanism, but noted that every affected autoimmune disorder involved dysfunction of the lymphatic system.

The experimental cancer treatment is not expected to receive FDA approval for general use until at least 2010. Once that approval is in place, however, doctors will be free to prescribe the relevant pharmaceuticals for off-label uses, including management of autoimmune disease.

#

If you would like more information about this topic, or if you wish to schedule an interview, please contact Mark Johnson at m.johnson@massivedynamic.com.